NanoViricides (NNVC) announced it is forging ahead with its Measles drug development program. The company has commissioned an animal trial to evaluate certain drug candidates, including NV-387, in a lethal animal infection model using specially modified mice. The study will initiate as soon as the animals arrive and are acclimatized. President and Executive Chairman Anil Diwan stated confidence in NV-387’s activity against Measles virus, noting it cured lethal RSV infection in animals. There is no approved drug for Measles infection.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NNVC: